- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01630226
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland
This is a single center, non-randomized, open label phase II trial to evaluate the clinical and pathologic response of neoadjuvant cisplatin-monotherapy in BRCA1 positive patients. The study will enroll patients with diagnosed breast cancer with a BRCA1 mutation. Patients will be eligible if they have primary breast cancer (measured on mammogram and ultrasound or MRI) and confirmed histological diagnosis of invasive breast cancer by core biopsy. If axilla lymph nodes will be suspected then fine needle aspiration biopsy will be performed. Patients will be drawn from one of three oncology centers: Szczecin, Bielsko-Biała and Kraków.
Patients will obtain staging investigations and will be monitored. Once entry criteria is met and consent obtained, all patients will obtain baseline staging investigation within 3 weeks of trial registration. Routine investigations will include staging scans: mammography, ultrasound of the breast and axilla (assessment of breast tumor and axilla lymph nodes), assessment of chest/abdomen/pelvis (plain film, Computed Tomography [CT] and/or ultrasound as per local standards) and baseline blood work (Complete Blood Count [CBC], electrolytes, creatinine, Liver Function Tests [LFTs], calcium, albumin).
Once staging investigations are complete, all patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy). Clinical response will be evaluated every three weeks by the treating physician while on chemotherapy (tumour of the breast and axilla lymph nodes). After four cycles of chemotherapy the patient will then undergo definitive surgery (mastectomy or breast-conserving surgery). Sentinel lymph nodes procedure will be performed. In case of positive lymph nodes standard lymph nodes surgery will be performed. Pathological complete response will defined as no evidence of residual tumor in the breast and the axilla. There may be evidence of ductal carcinoma in situ. The pathology will reviewed by two independent pathologists.
Following surgery patients will receive standard adjuvant chemotherapy at the discretion of the treating physician and if indicated, the patient will also receive radiotherapy and/or hormonal therapy and/or adjuvant trastuzumab at the description of the treating physician.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Tomasz Byrski, MD, PhD
- Telefonnummer: 48-501-225-501
- E-mail: tomekbyr@wp.pl
Studiesteder
-
-
-
Szczecin, Polen
- Rekruttering
- Pomenarian Medical University
-
Kontakt:
- Tomasz Byrski, MD, PhD
- Telefonnummer: 48-501-225-501
- E-mail: tomekbyr@wp.pl
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
- Histologically or cytologically proven diagnosis of invasive breast cancer (stage I-III).
- Documentation of the presence of a germ-line BRCA1 mutation
- Measurable disease of any size by mammography or ultrasound.
- Female diagnosed with breast cancer between the ages of 20 to 70.
- Eastern Cooperative Oncology Group [ECOG] performance status of 0 and 1.
- Evidence of adequate organ function (liver, bone marrow, kidney)
- Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment.
- Willingness and ability to comply with scheduled visits, treatment plans laboratory tests, and other study procedures.
- Polish resident.
Exclusion Criteria:
Patients presenting with any of the following will not be included in the trial:
- Previous chemotherapy for current cancer.
- Previous or current diagnosis of any other malignancy except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- Receiving any medication that may markedly affect renal function.
- Pregnant or breastfeeding women.
- Uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Neoadjuvant Cisplatin Chemotherapy
|
Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Pathologic Complete Response
Tidsramme: Four Months
|
Four Months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Tomasz Byrski, MD, PhD, Pomenarian Medical University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- BN-001/83/07-B
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med BRCA1 mutation
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARekruttering
-
University of PennsylvaniaRekruttering
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Ukendt
-
Memorial Sloan Kettering Cancer CenterUniversity of Pennsylvania; University of California, Los Angeles; Dana-Farber... og andre samarbejdspartnereAktiv, ikke rekrutterende
-
European Institute of OncologyAfsluttetBRCA1 mutation | BRCA2 mutation | Psykosociale faktorerItalien
-
University of PennsylvaniaInovio PharmaceuticalsRekruttering
-
nVision MedicalAfsluttetBRCA1 mutation | BRCA2 mutation | Atypi mistænkelig for malignitetForenede Stater
-
University Hospital, MontpellierAfsluttet
-
University of California, San FranciscoGlaxoSmithKlineRekrutteringMetastatisk fast tumor | BRCA1 mutation | BRCA2 mutation | PALB2-genmutation | ATM-genmutationForenede Stater
-
University Hospital, GhentFox Chase Cancer Center; Ziekenhuis Oost-LimburgAfsluttetBRCA1 mutation | BRCA2 mutation | hCGBelgien
Kliniske forsøg med Neoadjuvant Cisplatin Chemotherapy
-
Boston Medical CenterAmerican Cancer Society, Inc.Tilmelding efter invitation
-
West China Second University HospitalRekrutteringNeoadjuverende kemoterapi | Epitelkarcinom, ovarieKina
-
Insmed IncorporatedAfsluttetOsteosarkom MetastatiskForenede Stater
-
Cedars-Sinai Medical CenterRekrutteringHPV-positivt orofaryngealt planocellulært karcinomForenede Stater
-
Privo TechnologiesNational Cancer Institute (NCI)AfsluttetOralt planocellulært karcinomForenede Stater
-
Lawson Health Research InstituteRekrutteringLokalt avanceret hoved- og halspladecellekarcinomCanada
-
Taiho Oncology, Inc.Quintiles, Inc.AfsluttetMavekræftForenede Stater, Canada
-
Sun Yat-sen UniversityAktiv, ikke rekrutterendeNasopharyngealt karcinomKina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial... og andre samarbejdspartnereAktiv, ikke rekrutterendeNasopharyngealt karcinom | Nasopharyngeale neoplasmer | Nasopharyngeale sygdomme | Neoplasma i hoved og halsKina
-
Fujian Cancer HospitalIkke rekrutterer endnuNasopharyngealt karcinomKina